Canada Spends Logo

Explore our Budget 2026 analysis

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

University of Calgary

$120,000.00

Mitochondrial Regulation of Inflammatory Bowel Disease by ATG16L1

FY 2025-26

Summary
Inflammatory Bowel Disease (IBD) is a long-term condition that causes persistent inflammation in the digestive tract. Scientists now understand that mitochondria - the "powerhouses" of our cells - play a crucial role in controlling inflammation and maintaining gut health. When mitochondria become damaged or fail to function properly, this disruption can contribute to the development of IBD. Our research focuses on a gene called ATG16L1, which is one of the most commonly altered genes in people with IBD. We aim to understand how changes in this gene affect mitochondrial health and how that leads to inflammation in the gut. In the first part of our study, we will examine what happens to mitochondria in gut cells when the ATG16L1 gene is missing. Using advanced imaging and mitochondrial activity tests, we will assess whether the loss of this gene alters mitochondrial dynamics and energy production. Next, we will study a specific genetic change called the T300A variant of ATG16L1, which is frequently found in people with IBD. Using CRISPR gene-editing tools, we will introduce this variant into cells to see how it affects mitochondria compared to normal cells. In the third part, we will explore how mitochondrial dysfunction caused by ATG16L1 changes might activate cellular pathways that drive inflammation. We suspect that damaged mitochondria may release mitochondrial DNA inside the cell, triggering alarm signals and worsening inflammation. Finally, we will use 3D "mini-guts" grown from patient cells carrying ATG16L1 mutations to test our findings in a realistic, patient-like model. By connecting these findings, our research aims to uncover how ATG16L1 maintains mitochondrial health and prevents gut inflammation. Ultimately, this knowledge could help identify new early markers of IBD and guide the development of therapies that protect mitochondrial health, offering more personalized and effective treatment options for people living with IBD.
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
559821
Name
Jaiswal Amit
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Mitochondrial Regulation of Inflammatory Bowel Disease by ATG16L1
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Atg16l1; Autophagy; Confocal Microscopy; Crispr; Inflammation; Inflammatory Bowel Disease (Ibd); Mitochondrial Dysfunction; Mitochondrial Respiration; Mitophagy; Organoids
Abstract
Inflammatory Bowel Disease (IBD) is a long-term condition that causes persistent inflammation in the digestive tract. Scientists now understand that mitochondria - the "powerhouses" of our cells - play a crucial role in controlling inflammation and maintaining gut health. When mitochondria become damaged or fail to function properly, this disruption can contribute to the development of IBD. Our research focuses on a gene called ATG16L1, which is one of the most commonly altered genes in people with IBD. We aim to understand how changes in this gene affect mitochondrial health and how that leads to inflammation in the gut. In the first part of our study, we will examine what happens to mitochondria in gut cells when the ATG16L1 gene is missing. Using advanced imaging and mitochondrial activity tests, we will assess whether the loss of this gene alters mitochondrial dynamics and energy production. Next, we will study a specific genetic change called the T300A variant of ATG16L1, which is frequently found in people with IBD. Using CRISPR gene-editing tools, we will introduce this variant into cells to see how it affects mitochondria compared to normal cells. In the third part, we will explore how mitochondrial dysfunction caused by ATG16L1 changes might activate cellular pathways that drive inflammation. We suspect that damaged mitochondria may release mitochondrial DNA inside the cell, triggering alarm signals and worsening inflammation. Finally, we will use 3D "mini-guts" grown from patient cells carrying ATG16L1 mutations to test our findings in a realistic, patient-like model. By connecting these findings, our research aims to uncover how ATG16L1 maintains mitochondrial health and prevents gut inflammation. Ultimately, this knowledge could help identify new early markers of IBD and guide the development of therapies that protect mitochondrial health, offering more personalized and effective treatment options for people living with IBD.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Jaiswal, Amit
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~